Next Article in Journal
Asymmetric Dimethylarginine as a Surrogate Marker of Endothelial Dysfunction and Cardiovascular Risk in Patients with Systemic Rheumatic Diseases
Next Article in Special Issue
Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells
Previous Article in Journal
Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
Previous Article in Special Issue
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2012, 13(10), 12287-12314; doi:10.3390/ijms131012287

Phosphoproteomics and Lung Cancer Research

1
Hospital Universitario Niño Jesús, Department of Oncohematology of Children, Madrid 28009, Spain
2
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong
*
Author to whom correspondence should be addressed.
Received: 8 August 2012 / Revised: 14 September 2012 / Accepted: 19 September 2012 / Published: 26 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
View Full-Text   |   Download PDF [314 KB, uploaded 19 June 2014]   |  

Abstract

Massive evidence suggests that genetic abnormalities contribute to the development of lung cancer. These molecular abnormalities may serve as diagnostic, prognostic and predictive biomarkers for this deadly disease. It is imperative to search these biomarkers in different tumorigenesis pathways so as to provide the most appropriate therapy for each individual patient with lung malignancy. Phosphoproteomics is a promising technology for the identification of biomarkers and novel therapeutic targets for cancer. Thousands of proteins interact via physical and chemical association. Moreover, some proteins can covalently modify other proteins post-translationally. These post-translational modifications ultimately give rise to the emergent functions of cells in sequence, space and time. Phosphoproteomics clinical researches imply the comprehensive analysis of the proteins that are expressed in cells or tissues and can be employed at different stages. In addition, understanding the functions of phosphorylated proteins requires the study of proteomes as linked systems rather than collections of individual protein molecules. In fact, proteomics approaches coupled with affinity chromatography strategies followed by mass spectrometry have been used to elucidate relevant biological questions. This article will discuss the relevant clues of post-translational modifications, phosphorylated proteins, and useful proteomics approaches to identify molecular cancer signatures. The recent progress in phosphoproteomics research in lung cancer will be also discussed.
Keywords: lung cancer; mass spectrometry; phosphoproteomics; post-translational modification; signaling pathway lung cancer; mass spectrometry; phosphoproteomics; post-translational modification; signaling pathway
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

López, E.; Cho, W.C.S. Phosphoproteomics and Lung Cancer Research. Int. J. Mol. Sci. 2012, 13, 12287-12314.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top